Next Article in Journal
Bioengineering Clinically Relevant Cardiomyocytes and Cardiac Tissues from Pluripotent Stem Cells
Next Article in Special Issue
The Interplay between Immune System and Microbiota in Inflammatory Bowel Disease: A Narrative Review
Previous Article in Journal
Is High-Intensity Interval Training Suitable to Promote Neuroplasticity and Cognitive Functions after Stroke?
Previous Article in Special Issue
Dysbiosis in the Development of Type I Diabetes and Associated Complications: From Mechanisms to Targeted Gut Microbes Manipulation Therapies
Review

Fecal Microbiota Transplantation during and Post-COVID-19 Pandemic

1
School of Engineering, University of British Columbia, Kelowna, BC V1V 1V7, Canada
2
Division of Gastroenterology, Department of Medicine, University of Alberta, Edmonton, AB T6G 2G3, Canada
*
Author to whom correspondence should be addressed.
Academic Editor: Maria Pascual
Int. J. Mol. Sci. 2021, 22(6), 3004; https://doi.org/10.3390/ijms22063004
Received: 18 February 2021 / Revised: 9 March 2021 / Accepted: 11 March 2021 / Published: 16 March 2021
(This article belongs to the Special Issue Gut Microbiota and Immunity)
COVID-19 is a major pandemic facing the world today, which has implications on current microbiome-based treatments such as fecal microbiota transplantation (FMT) used for recurrent Clostridioides difficile infections. The bidirectional relationship between the inhabitants of our gut, the gut microbiota, and COVID-19 pathogenesis, as well as the underlying mechanism involved, must be elucidated in order to increase FMT safety and efficacy. In this perspective, we discuss the crucial cross-talk between the gut microbiota and the lungs, known as the gut–lung axis, during COVID-19 infection, as well as the putative effect of these microorganisms and their functional activity (i.e., short chain fatty acids and bile acids) on FMT treatment. In addition, we highlight the urgent need to investigate the possible impact of COVID-19 on FMT safety and efficacy, as well as instilling stringent screening protocols of donors and recipients during COVID-19 and post-COVID-19 pandemic to produce a cohesive and optimized FMT treatment plan across all centers and in all countries across the globe. View Full-Text
Keywords: fecal microbiota transplantation (FMT); Clostridioides difficile infection (CDI); gut microbiome; COVID-19; policy guidelines fecal microbiota transplantation (FMT); Clostridioides difficile infection (CDI); gut microbiome; COVID-19; policy guidelines
Show Figures

Figure 1

MDPI and ACS Style

Kazemian, N.; Kao, D.; Pakpour, S. Fecal Microbiota Transplantation during and Post-COVID-19 Pandemic. Int. J. Mol. Sci. 2021, 22, 3004. https://doi.org/10.3390/ijms22063004

AMA Style

Kazemian N, Kao D, Pakpour S. Fecal Microbiota Transplantation during and Post-COVID-19 Pandemic. International Journal of Molecular Sciences. 2021; 22(6):3004. https://doi.org/10.3390/ijms22063004

Chicago/Turabian Style

Kazemian, Negin, Dina Kao, and Sepideh Pakpour. 2021. "Fecal Microbiota Transplantation during and Post-COVID-19 Pandemic" International Journal of Molecular Sciences 22, no. 6: 3004. https://doi.org/10.3390/ijms22063004

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop